Advanced Phenotypic Analysis

 
 
 
 
 
 
 
For Immediate Release
Tuesday, September 13, 2005
 
Contact:  Stacy Montgomery, Ph.D.  
  Biolog, Inc.
  (510) 785-2564 ext. 409
 

BIOLOG ANNOUCES FIRST PHENOTYPE MICROARRAYPANELS FOR USE WITH MAMMALIAN CELL LINES

 

Hayward , CA- September 13, 2005 - Biolog, Inc. announced today its first Phenotype MicroArray™ (PM) cell based assays for use with mammalian cell lines. The mammalian cell capability is added to the expanding list of uses of PM technology for a variety of research applications including drug discovery, functional genomics, and cellular toxicology. PM technology has already been applied for use with a variety of microbial cells important in disease and industrial use, specifically bacteria, yeast and filamentous fungi. The PM mammalian cell panels also have very broad utility. They have already been optimized for use in a wide variety of human cell lines, including liver cell lines (HepG2, C3A), leukemia cell lines (CRF- CEM , HL60), a colon cancer line (Colo 205), a non-small cell lung cancer line (A549), a prostate cancer cell line (PC-3), a mouse cell line (TK-1) and non-immortalized mammalian cell lines. The new mammalian cell PM technology is being exhibited for the first time at the Society for Biomolecular Screening (SBS) conference this week in Geneva, Switzerland .

The mammalian cell assays are an important advance in this innovative and unique technology platform. The first PM mammalian panels to be released provide 384 assays that probe different metabolic energy-producing pathways of cells. “I expect these assays will become an essential research tool for all pharma companies working on drugs to treat diabetes, obesity, or other disorders of energy metabolism”, says Barry Bochner, Chairman and CSO at Biolog. “We have found that cells from different organs have a different range of biochemicals from which they can derive energy. There is a lot more to cellular energy production than just glucose metabolism. Our PM panels allow scientists, for the first time, to simultaneously measure rates of metabolism of many other catabolic pathways including other sugars, amino acids, and carboxylic acids. You can add a drug or a metabolically active hormone to a cell and comprehensively measure its impact on all of these energy-producing pathways in that cell. When used with Biolog’s OmniLog® instrument, one can measure rates in nearly 5,000 assays at a time. The colorimetric technology format is compatible with the widely accepted 96-well and 384-well configurations and therefore can fit with robotic automation already in place in pharma and biotech companies as well as university and government research laboratories.”

A second important use of the new PM mammalian panels is as a tool to fingerprint cell lines. Cells from different organs have different energy metabolism pathways active. For example, liver cells have a large number of these pathways and are easily differentiated from blood cells, which are relatively limited. Cells from other organs are intermediate. Therefore, the new PM panels allow scientists a simple way to characterize and fingerprint the cell line that they are using. There appears to be subtle changes in the catabolic metabolism of cells when they become cancerous, or when they age and senesce. Therefore the technology is also expected to draw interest from researchers working on cancer and aging, and also as a QC tool for anyone working with cell lines that wants to check the metabolism of their cells to verify that the cells are not changing over the course of experiments in which the cell lines are repeatedly passaged.

Phenotype MicroArrays represent a fundamental technology platform that allows scientists to easily and efficiently test hundreds to thousands of cellular traits simultaneously. The company’s Phenotype MicroArray technology and OmniLog PM System can be used in the discovery and development of new drugs and other bioactive agents for human, animal and plant health applications. The technology has the promise of determining cellular phenotypic expression in many areas of basic and applied research. The two most important near term applications are using PMs to determine the effect of genetic changes on cells and to determine the effect of drugs on cells, both mode of action and toxicology.

Biolog, a privately held company based in Hayward, CA , is a pioneer in the development of powerful new cell analysis tools for solving critical problems in clinical, pharmaceutical, and biotechnology research and development. The PM product line joins the innovative award winning microbial identification products offered by Biolog, Inc. Further information can be obtained at the company’s website, www.biolog.com.
 
 
 
All content copyright Biolog, Inc. © 2007. All trademarks and registered trademarks are the property of their respective companies. Use of this web site indicates that you accept the Terms and Conditions. Please see our User Privacy policy. If you have any questions or comments about Biolog's web site please contact us at info@biolog.com.